Difference between revisions of "Chronic myelomonocytic leukemia"
Jump to navigation
Jump to search
(Created page with "'''Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.''' Is th...") |
|||
| Line 8: | Line 8: | ||
===Regimen, Grövdal et al. 2010=== | ===Regimen, Grövdal et al. 2010=== | ||
| − | |||
*[[Azacitidine (Vidaza)]] 60 mg/m2 SC daily on days 1 to 5 | *[[Azacitidine (Vidaza)]] 60 mg/m2 SC daily on days 1 to 5 | ||
Revision as of 14:32, 14 June 2013
Use of this site is subject to you reading and agreeing with the terms set forth in the disclaimer.
Is there a regimen missing from this list? Would you like to share a different dosage/schedule or an additional reference for a regimen? Have you noticed an error? Do you have an idea that will help the site grow to better meet your needs and the needs of many others? You are invited to contribute to the site.
Azacitidine (Vidaza)
Regimen, Grövdal et al. 2010
- Azacitidine (Vidaza) 60 mg/m2 SC daily on days 1 to 5
28-day cycles
References
- Grövdal M, Karimi M, Khan R, Aggerholm A, Antunovic P, Astermark J, Bernell P, Engström LM, Kjeldsen L, Linder O, Nilsson L, Olsson A, Holm MS, Tangen JM, Wallvik J, Oberg G, Hokland P, Jacobsen SE, Porwit A, Hellström-Lindberg E. Maintenance treatment with azacytidine for patients with high-risk myelodysplastic syndromes (MDS) or acute myeloid leukaemia following MDS in complete remission after induction chemotherapy. Br J Haematol. 2010 Aug;150(3):293-302. doi: 10.1111/j.1365-2141.2010.08235.x. Epub 2010 May 20. link to original article contains verified protocol PubMed